HIV Infections Clinical Trial
Official title:
Evaluation of the Population-level Impact of Prevention of Mother-to-Child HIV Transmission Program Option B+ in Zimbabwe
Verified date | May 2023 |
Source | University of California, Berkeley |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study evaluates the impact of Zimbabwe's program for the prevention of mother-to-child HIV transmission (PMTCT) on vertical transmission of HIV infection and HIV-free survival among infants exposed to HIV. The study will test the hypothesis that the accelerated PMTCT program in Zimbabwe will result in fewer new HIV infections in infants and will increase infant survival.
Status | Completed |
Enrollment | 30642 |
Est. completion date | January 2019 |
Est. primary completion date | July 2018 |
Accepts healthy volunteers | |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria Mothers-Infant pairs: - Mother or caregiver is 16 years of age or older - Delivered or provides care for an infant (alive or deceased) who is or who would have been 9-18 months of age at the time of the survey - Able and willing to provide written informed consent Exclusion Criteria Mothers-Infant pairs: - Mother or caregiver is younger than 16 years of age - Infant (alive or deceased) is not/would not have been 9-18 months of age at the time of the survey Inclusion Criteria Mothers/Caregivers: - At least 16 years of age or older - Delivered an infant (alive or deceased) who is or who would have been 19-36 months of age at the time of the survey - Able and willing to provide written informed consent Exclusion Criteria Mothers/Caregivers: - Mother or caregiver is younger than 16 years of age - Infant (alive or deceased) is not/would not have been 19-36 months of age at the time of the survey Inclusion Criteria Healthcare Staff: - At least 18 years of age or older - Currently providing PMTCT services at one of the 157 selected facilities - Able and willing to provide written informed consent Exclusion Criteria Healthcare Staff: - Health care staff is younger than 18 years of age - Health care staff is not currently providing PMTCT services at one of the 157 selected facilities Inclusion Criteria Providers: - At least 18 years of age or older - Currently providing ANC or ART care directly to clients at one of the 20 purposefully selected facilities - Splitting time as a provider between one or more of the following HIV services: HIV testing and counseling (HTC), prevention of mother-to-child transmission (PMTCT), and male circumcision (MC) - Able and willing to provide written informed consent Exclusion Criteria Providers: - Provider is younger than 18 years of age - Currently not providing ART care directly to clients at one of the 20 purposefully selected facilities - Does not split time as a provider between one or more of the following HIV services: HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), and male circumcision (MC) Inclusion Criteria Patients: - At least 18 years of age or older - Received HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), or male circumcision (MC) services at one of the 20 purposefully selected facilities on the day of the interview - Able and willing to provide verbal consent Exclusion Criteria Patients: - Patient is younger than 18 years of age - Did not receive HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), or male circumcision (MC) services at one of the 20 purposefully selected facilities on day of interview |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of California, Berkeley | Centre for Sexual Health and HIV/AIDS Research Zimbabwe (CeSHHAR Zimbabwe), Children's Investment Fund Foundation, Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT)., Elizabeth Glaser Pediatric AIDS Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Liverpool School of Tropical Medicine, Ministry of Health and Child Welfare, Zimbabwe |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vertical transmission of HIV infection | Proportion of infants born to HIV-infected mothers who were HIV-infected | 9-18 months after birth | |
Primary | HIV-free survival among infants exposed to HIV | Proportion of infants born to HIV-infected mothers who were alive and HIV-uninfected | 9-18 months after birth | |
Secondary | Retention of mothers in antiretroviral therapy services (ART) services after weaning | The proportion of HIV-infected mothers who were initiated on ART and who continued ART after weaning | 19-36 months postpartum | |
Secondary | Time between weaning and discontinuation of antiretroviral therapy services (ART) among mothers who did not continue ART after weaning | Average time between delivery and discontinuation of ART among those mothers who did not continue ART | 19-36 months postpartum | |
Secondary | Heterogeneity of the impact of Option B+ on HIV-free survival among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilities | HIV-free survival in health facility catchment areas stratified by the extent of integration of PMTCT and ART services at the health facility | Baseline | |
Secondary | Heterogeneity of the impact of Option B+ on mother-to-child transmission of HIV (MTCT) among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilities | MTCT in health facility catchment areas stratified by the extent of integration of PMTCT and ART services at the health facility | Baseline | |
Secondary | Cost-effectiveness of Option B+ compared to the standard of care before Option A | Facility costing data and HIV-free survival and MTCT in health facility catchment areas in 2012 compared to 2017 | Baseline | |
Secondary | Cost-effectiveness of Option B+ compared to Option A | Facility costing data and HIV-free survival and MTCT in health facility catchment areas in 2012 compared to 2014 | Baseline | |
Secondary | Variability in health facility accesibility | Accessibility of health facilities assessed using exit interviews with patients receiving care at health facilities | Baseline | |
Secondary | Variability in health facility quality of available services | Quality of available services at health facilities assessed using exit interviews with patients receiving care at health facilities, and clinical vignettes and time and motion studies with healthcare providers at health facilities | Baseline | |
Secondary | Variability in health facility appropriateness of available services | Appropriateness of available HIV testing and counseling (HTC), prevention of mother-to-child transmission of HIV (PMTCT) and male circumcision (MC) services assessed using clinical vignettes with healthcare providers at health facilities | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Recruiting |
NCT06033547 -
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT06072443 -
AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 |